Angiotech Pharmaceuticals, Inc.

Services

Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction

CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem-® in the treatment of acute myocardial infarction (AMI). The companies believe that...

Read More »
Services

Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction

CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStemÂ-® in the treatment of acute myocardial infarction (AMI). The companies believe that...

Read More »
Adhesives & Sealants

Absorbable Sutures eliminate use of knots.

Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...

Read More »
Adhesives & Sealants

Absorbable Sutures eliminate use of knots.

Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...

Read More »
Fasteners & Hardware

Angiotech Receives European Approval for Quill® SRS Wound Closure Product

New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its Quill-® Self-Retaining System (SRS). Launched early in the year in the United States, Quill®...

Read More »
Fasteners & Hardware

Angiotech Receives European Approval for Quill-® SRS Wound Closure Product

New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its QuillÂ-® Self-Retaining System (SRS). Launched early in the year in the United States,...

Read More »
Health, Medical, & Dental Supplies and Equipment

Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS® Express2(TM) Coronary Stent System

Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....

Read More »
Health, Medical, & Dental Supplies and Equipment

Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS-® Express2(TM) Coronary Stent System

Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....

Read More »
Health, Medical, & Dental Supplies and Equipment

Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Approval for the TAXUS® Express2(TM) Stent System

VANCOUVER, April 3 - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner, Boston Scientific Corporation (NYSE:BSX), announced today that Boston Scientific has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to market its TAXUS-® Express2(TM)...

Read More »
Health, Medical, & Dental Supplies and Equipment

Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Approval for the TAXUS-® Express2(TM) Stent System

VANCOUVER, April 3 - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner, Boston Scientific Corporation (NYSE:BSX), announced today that Boston Scientific has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to market its TAXUSÂ-® Express2(TM)...

Read More »
Services

Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction

CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStem-® in the treatment of acute myocardial infarction (AMI). The companies believe that...

Read More »
Services

Athersys and Angiotech Announce Authorization of Phase I Intramyocardial Stem Cell U.S. Clinical Trial in Acute Myocardial Infarction

CLEVELAND, OH and VANCOUVER, Dec. 20 - Athersys, Inc. (NASDAQ:ATHX) and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX: ANP), announced today that Athersys has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the safety of MultiStemÂ-® in the treatment of acute myocardial infarction (AMI). The companies believe that...

Read More »
Adhesives & Sealants

Absorbable Sutures eliminate use of knots.

Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...

Read More »
Adhesives & Sealants

Absorbable Sutures eliminate use of knots.

Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures are made from rapidly resorbing polymer, which is intended primarily for superficial wound closure applications. Available in 3 diameters, FDA-approved products feaure helical barbed design that enables surgeons to suture without use of knots. This minimizes complications associated with knots and promotes wound healing as well as...

Read More »
Fasteners & Hardware

Angiotech Receives European Approval for Quill® SRS Wound Closure Product

New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its Quill-® Self-Retaining System (SRS). Launched early in the year in the United States, Quill®...

Read More »
Fasteners & Hardware

Angiotech Receives European Approval for Quill-® SRS Wound Closure Product

New Class of Wound Closure Product Expected to Launch in Europe Mid-Year VANCOUVER, May 17 -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its QuillÂ-® Self-Retaining System (SRS). Launched early in the year in the United States,...

Read More »
Health, Medical, & Dental Supplies and Equipment

Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS® Express2(TM) Coronary Stent System

Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....

Read More »
Health, Medical, & Dental Supplies and Equipment

Angiotech's Corporate Partner, Boston Scientific, Announces Japanese Launch of TAXUS-® Express2(TM) Coronary Stent System

Reimbursement granted by National Health Insurance System VANCOUVER, May 8 // -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(NASDAQ:TSX:)(NASDAQ:ANP), a global specialty pharmaceutical and medical device company, along with its corporate partner Boston Scientific Corporation (NYSE: BSX) today announced the launch of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan....

Read More »
Company News

Angiotech to Market Vascular Wrap(TM)/e0PTFE Graft Combination Product through its Own European Sales and Distribution Networks

VANCOUVER, May 10 / -- Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation ( Edwards"), regarding the distribution of Angiotech's Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product. Angiotech now has the exclusive rights to distribute the...

Read More »
Company News

Angiotech to Market Vascular Wrap(TM)/e0PTFE Graft Combination Product through its Own European Sales and Distribution Networks

VANCOUVER, May 10 / -- Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation ( Edwards"), regarding the distribution of Angiotech's Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product. Angiotech now has the exclusive rights to distribute the...

Read More »

All Topics